Erratum: Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study (Journal of Investigative Dermatology (2015) 135 (67-75)) DOI: 10.1038/jid.2014.306)